{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:39:11Z","timestamp":1718138351724},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T00:00:00Z","timestamp":1469836800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Egis Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s12325-016-0392-8","type":"journal-article","created":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T05:36:14Z","timestamp":1469856974000},"page":"1771-1781","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Short-Term Cardioprotective Effects of the Original Perindopril\/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Tam\u00e1s","family":"Forster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba Andr\u00e1s","family":"D\u00e9zsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,30]]},"reference":[{"key":"392_CR1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"392_CR2","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1161\/CIRCULATIONAHA.106.674143","volume":"115","author":"RA Kronmal","year":"2007","unstructured":"Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;115:2722\u201330.","journal-title":"Circulation"},{"issue":"38","key":"392_CR3","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"3","key":"392_CR4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40256-013-0058-8","volume":"14","author":"CA D\u00e9zsi","year":"2014","unstructured":"D\u00e9zsi CA. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs. 2014;14(3):167\u201373.","journal-title":"Am J Cardiovasc Drugs"},{"key":"392_CR5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, et al. The European trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"392_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"392_CR7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"Pitt","year":"2000","unstructured":"Pitt, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503\u201310.","journal-title":"Circulation"},{"key":"392_CR8","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"S Nissen","year":"2004","unstructured":"Nissen S, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217\u201326.","journal-title":"JAMA"},{"issue":"3","key":"392_CR9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cardiores.2006.04.013","volume":"71","author":"S Batova","year":"2006","unstructured":"Batova S, et al. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc Res. 2006;71(3):478\u201385.","journal-title":"Cardiovasc Res"},{"issue":"12A","key":"392_CR10","doi-asserted-by":"crossref","first-page":"92H","DOI":"10.1016\/S0002-9149(99)00269-6","volume":"83","author":"S Mital","year":"1999","unstructured":"Mital S, et al. Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts. Am J Cardiol. 1999;83(12A):92H\u20138H.","journal-title":"Am J Cardiol"},{"issue":"7","key":"392_CR11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40261-013-0086-9","volume":"33","author":"VL Nagy","year":"2013","unstructured":"Nagy VL. Twenty-four-hour ambulatory blood pressure reduction with a perindopril\/amlodipine fixed-dose combination. Clin Drug Investig. 2013;33(7):469\u201376.","journal-title":"Clin Drug Investig"},{"key":"392_CR12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895\u2013906.","journal-title":"Lancet"},{"key":"392_CR13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ahj.2009.12.042","volume":"159","author":"ME Bertrand","year":"2010","unstructured":"Bertrand ME, et al. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159:795\u2013802.","journal-title":"Am Heart J"},{"key":"392_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjcard.2013.03.026","volume":"112","author":"G Bakris","year":"2013","unstructured":"Bakris G, et al. Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. Am J Cardiol. 2013;112:255\u20139.","journal-title":"Am J Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0392-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:33:49Z","timestamp":1498332829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0392-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,30]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0392-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,30]]}}}